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1. Introduction
C hronic obstructive pulm onary d isease  
(COPD) is characterised by chronic persistent 
airways obstruction, which is not reversible but 
may vary in intensity. COPD includes chronic 
bronchitis, bronchiolitis and emphysema [1], In 
most patients more than one component is pre­
sent, and it is often not possible to distinguish 
one from the other. Symptoms of COPD include 
chronic cough, production o f sputum and (exer­
tional) dyspnoea. Recurrent exacerbations may 
occur, caused in particular by viral and bacterial 
infections. If untreated, the disease is character­
ized by a progressive deterioration of lung func­
tion. This may eventually result in total respira­
tory insufficiency.
The most important risk factor of COPD is 
smoking, which causes various abnormalities in 
the airways and lung parenchyma. Epithelial 
changes in the airways include metaplasia, goblet 
cell hyperplasia, destruction of ciliated epithe­
lium and increased production and accumulation 
of sputum, and a chronic inflammatory process in 
the airway wall. In the parenchyma, destruction
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of the alveolar structures leads to emphysema. In 
both processes oxygen-derived free radicals play 
an important role.
2. Free radicals or oxidants and antioxidants
The free radicals that are important for the 
airways are either inhaled or released by inflam­
matory cells. Inhaled free radicals are derived 
from tobacco smoke or air pollution such as ozone  
and N 0 2. Endogenously, free radicals are gener­
ated by neutrophils and alveolar macrophages [2]. 
These activated cells, present in large numbers in 
the airways, are characteristic o f the inflamma­
tory process induced by the inhalation o f cigarette 
smoke. Tobacco sm oke, therefore, leads to an 
increased load o f free radicals on the lungs, both 
directly by inhalation and indirectly by the in­
flammatory com ponent.
Free radicals play also a role in the develop­
m ent of emphysema. Em physem a is caused by a 
disturbance of the e lastase/an tie lastase  balance 
in favour o f elastase, which leads to a breakdown 
of the pulmonary structure by destruction of 
elastin fibres, collagen and proteoglycans. In 
bronchitis, granulocytes lead to increased levels 
of elastase. In addition, free radicals are capable
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of inactivating antielastase. An increase in the 
load o f free radicals induces a further increase of 
elastase activity and may thus contribute to the 
developm ent o f emphysema.
The organism is capable of protecting itself 
against free radicals by means of antioxidants. In 
the lungs antioxidants are present in mucus, sur­
factant and epithelial lining fluid, and in lung 
tissue, both intra- and extracelluiarly. One of the 
major antioxidant defense mechanisms is the glu­
tathione redox cycle.
On the basis o f these principles an improve­
m ent in antioxidant protection may lead to a 
recovery o f the balance between free radicals and 
antioxidants and of the balance between elastase 
and antielastase. The question is whether this 
opens up a perspective in the treatment of COPD.
3, Experimental studies with iV-acetylcysteine
Af-Acetylcysteine (N A C ) is a thiol-containing 
compound which acts as a precursor of glu­
tathione (GSH). N A C  has an antioxidant effect in 
at least three ways [3]. The first effect is the 
direct non-enzymatic reaction of N A C  with free 
radicals. Adding N A C  in in-vitro experiments 
caused a decrease of hydrogen peroxide (H 20 2)- 
induced damage, which is explained by a direct 
reaction between NAC and H 20 2. The protec­
tion is also linked to an increase in the intracellu­
lar GSH concentration. A t a cellular level, there­
fore, N A C  improves antioxidant protection via 
GSH metabolism. Finally3 NAC supports in vivo 
liver cell synthesis o f GSH, which is transported 
to the threatened organic system through the 
blood. A nother possibility is that the cysteine 
m olecule from N A C , released in the intestine 
and liver, intracellularly supports the production 
of GSH when transported to the target organ.
In m odels using cell systems it has been 
demonstrated that NAC and GSH reduce or pre­
vent the adverse effects o f cigarette smoke on the 
function o f neutrophils [4] and alveolar macro­
phages [5]. In rats the secretory cell hyperplasia 
induced by smoke was also attenuated by adding 
N A C  to the food [6]. Furthermore, NAC also 
appeared to protect against the cytotoxic effects
of tobacco smoke condensate in cell cultures ol 
human fibroblasts [7], These studies with cell 
cultures and in animals support the concept that 
free radicals play a role in the effects o f smoke on 
the airways, and that these effects can be inhib­
ited by GSH and NAC.
The role of free radicals has also been investi­
gated in humans. Cysteine and GSH concentra­
tions in plasma and BAL fluid increased after 
oral treatment with 600 mg NAC [8], After oral 
treatment NAC is quickly reduced to cysteine in 
the liver and intestine. This is a precursor in the 
biosynthesis of GSH, which is produced in the 
liver and lung cells.
In smokers the number of alveolar macro­
phages and neutrophils is increased in broncho- 
alveolar lavage (BAL) fluid as a sign of chronic 
inflammation in the airways. These cells release 
an increased amount of free radicals, demonstrat­
ing enhanced oxidative activity of inflammatory 
cells [2,9]. These changes can in part be pre­
vented by oral NAC. The drug reduced humoral 
markers of inflammatory cell activity in BAL fluid 
from smokers. Bergstrand and co-workers showed 
that oral treatment with NAC reduced the pro­
duction of free radicals by alveolar macrophages 
[10]. In healthy smokers, significant reductions in 
the BAL fluid content of lactoferrin, eosinophilic 
cationic protein (ECP), and chemotactic activity 
of neutrophils were found after treatment with 
NAC 200 mg t.i.d. for 8 weeks [11]. After a 
similar dose the number o f lymphocytes and the 
secretion  of leukotriene B 4 by alveolar  
macrophages increased in the BAL fluid o f  
healthy smokers [12]. These studies support the 
concept that free radicals in cigarette smokers 
can cause changes in the airways, which can be 
inhibited by oral use of NAC.
4. Effects of NAC in COPD
A number of investigations have shown that 
treatment with NAC results in a symptomatic 
improvement in COPD patients. Subjectively it 
concerns an improvement in the cough pattern 
(producing sputum more easily) and an increase 
in the amount of sputum with a decrease in
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viscosity and sputum purulence [13,14]. It has also 
been demonstrated that continuous use of NAC  
in COPD reduces the exacerbation rate as well as 
the number o f days of sick leave [13-16].
The question is which mechanism brings about 
the effect of NAC. An improvement of com­
plaints is possible by the direct mucolytic effect of 
NAC. Indeed, in patients whose ciliated epithe­
lium is intact, NAC can improve the mucociliary 
clearance [17]. However, in patients whose cili­
ated epithelium is largely destroyed, a mucolytic 
may not be expected to improve the mucociliary 
clearance [18]. There is strong evidence that the 
antioxidant effect of NAC is of great importance. 
This is based, among other things, on the obser­
vation that ionized glycerol, a mucolytic without 
antioxidant properties, is clinically less effective 
than NAC, a mucolytic with antioxidant proper­
ties. Ionized glycerol does improve the subjective 
symptoms in COPD but has, in contrast to NAC, 
no influence on the incidence o f exacerbations 
[19].
The decrease in the incidence of exacerbations 
can possibly be explained by a decrease in bacte­
rial colonization in the airways of chronic bron­
chitis during treatment with NAC [20]. Riise and 
colleagues demonstrated that chronic bronchitis 
leads to increased bronchial bacterial coloniza­
tion. During NAC treatment a lower number of 
bacterial-positive cultures was found.
Recently investigations have been carried out 
into the effect o f NAC on the course of lung 
function. A  current investigation in Sweden indi­
cates that in the long term the decrease in FEVX 
in COPD patients who use NAC 600 mg daily 
continuously is less than in a control group [21]. 
This favourable effect on lung function was ob­
served particularly in COPD patients over 50 
years. In both the NAC and the control group 
these patients were treated with bronchodilators 
and inhalation steroids in the usual way. The 
effect of NAC on the decline in pulmonary func­
tion was affirmed after 5 years of continuation of 
this study.
These data suggest that continuous use of NAC  
in COPD may result in an improvement o f symp­
toms and quality of life and in a decrease in the 
rate and severity of exacerbations. It also appears
that continuous use o f N A C  can contribute to 
improving the course o f the lung function in the 
long term. Effects o f N A C  may especially be 
expected in “older” C O PD  patients whose smok­
ing may be considered to be important as initiat­
ing factor and who regularly suffer from exacer­
bations (e.g., more than 3 tim es a year). In such 
treatment, N A C  will have to b e  used continu­
ously in doses o f at least 600 mg daily.
5. Conclusions
There are indications that a disturbance in the 
balance between oxidants and antioxidants plays 
a role in the pathophysiological process in COPD, 
in both chronic bronchitis and emphysema. Ex­
perimental studies show that N A C , cysteine and 
G SH  have favourable effects in protection against 
free radicals. In a number o f studies, treatm ent of 
chronic bronchitis with N A C  leads to an improve­
m ent o f the quality o f life, to a decrease of 
exacerbations and probably also to an improve­
m ent in the course o f lung function in the long 
term.
N A C  can be applied in a specific group of 
COPD patients. A  favourable effect may espe­
cially be expected in C O PD  caused by smoking 
and where a clear obstructive bronchitis is pre­
sent. If there are recurrent exacerbations, contin­
uous treatm ent with N A C  should be considered. 
In such treatment, N A C  will have to be used 
continuously in doses of at least 600 m g daily.
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